Publication | Closed Access

Designing quinoline-isoniazid hybrids as potent anti-tubercular agents inhibiting mycolic acid biosynthesis

BiosynthesisEngineeringBiochemistryMedicineSynthetic BiologyNatural Product BiosynthesisMycolic Acid BiosynthesisQuinoline-isoniazid HybridsPotent Anti-tubercular AgentsPharmacologyDrug DiscoveryNatural Product Synthesis